ACCESSIBILITY

24/7

Headlines

10:39

Intel’s decision to keep NEX signals stability for Israel’s 350 networking staff

10:29

Intel VP: “We had 11 or 12 layers of management... now it’s 5 or 6”

21:48

From textile recycling to autonomous vessels: The vision behind the Dream Team startups

20:25

ELNET: German business leaders “are looking with admiration and respect towards the Startup Nation”

Buzz

Most popular

Daily

Weekly

Check Point raises $1.75 billion, potentially eyeing AI expansion

Inside the mind of a Nobel physicist: John Martinis on the future of quantum computing

Hapag-Lloyd eyes ZIM acquisition, workers push back

Cybereason founders' 7AI raises record $130 million Series A in breakneck rise

Nice puts Actimize up for sale at a $1.5-2 billion price tag

More news

Immunotherapy

9 stories about Immunotherapy

Cancer Immunotherapy Startup NeoTX Raises $45 Million

20.02.20|Adi Pick

NeoTX uses STR to bind genetically engineered bacteria to tumor cells and simultaneously activate the antibacterial response of distant immune cells

Allogenic Immunotherapy Company Adicet Bio Raises $80 Million

02.10.19|Meir Orbach

Founded by Israeli chemist Aya Jakobovits, Adicet develops universal immune cell therapies based on gamma delta T cells to treat different forms of cancer

CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down

02.10.19|Tzally Greenberg

Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication

Compugen Falls 17% on Employee Cuts Announcement

27.02.19|Lilach Baumer

The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

12.10.18|Dror Reich

The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen

03.04.18|Lilach Baumer

The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer

The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy

Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur

Cell Immunotherapy Company Raises $8 Million

24.09.17|Lilach Baumer

Enlivex Therapeutics Ltd. is a clinical-stage company specializing in autoimmune and inflammatory conditions